Risk factor
Limited default risk
Profitability factor
Greatly undervalued vs peers
About
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue
Target Price
The average target price of 3933.HK is 15.1 and suggests 72.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i